Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients

Pancreas

Volumn 33, Issue 4, 2006, Pages 386-390

  Ikemoto, Tetsuya ^a   Yamaguchi, Takeshi ^a   Morine, Yuji ^a   Imura, Satoru ^a   Soejima, Yuji ^a   Fujii, Masahiko ^a   Maekawa, Yoichi ^a   Yasutomo, Koji ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Foxp3; Pancreatic cancer; Regulatory T cells; Tumor immunity

Indexed keywords

ANTIBODY; CA 19-9 ANTIGEN; CD57 ANTIGEN; DUPAN 2; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANALYSIS; ARTICLE; BLOOD; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; METASTASIS; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

AGED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 33750630223     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000240275.68279.13     Document Type: Article

References (18)

1. Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery. 2004;136:1003-1011.
2. Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg. 2000;232:786-795.
3. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
4. + T-cell into hepatic parenchyma in mice. J Med Invest. 2004;51:178-185.
5. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single IL-2 mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151.
6. + regulatory T cells from human peripheral blood. J Immunol. 2001;166:7282-7289.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057.
8. +CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444-1453.
9. + regulatory T cells by peripheral expansion. J Immunol. 2004;173:7259-7268.
10. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975.
11. Sobin LH, Wittekind LH. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. 6th ed. New York: Willy-Liss, Inc; 2002:87-90.
12. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
13. Nishiyama Y, Yamamoto Y, Yokoe K, et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med. 2005;19:491-497.
14. Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19:425-436.
15. + T cells. Clin Immunol. 2005;115:10-18.
16. Albert MH, Liu Y, Anasetti C, et al. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol. 2005;35:1-10.
17. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer. 2005;4:11.
18. Chua YJ, Cunningham D. Chemotherapy for advanced pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20(2):327-348.